Linvoseltamab (Lynozyfic, Regeneron Pharmaceuticals, Inc) plus carfilzomib (Kyprolis; Onyx Pharmaceuticals) induced deep, durable responses in patients with heavily pretreated relapsed refractory multiple myeloma (RRMM) with prior exposure to a prote... [4877 chars].. reed more
